FRESENIUS MEDICAL CARE - FINANCIAL FIGURES 2021

WHO WE ARE

Creating a future worth living. For our patients. Worldwide. Every day.

Fresenius Medical Care is the world's leading provider of products and services for individuals with kidney diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. We care for more than 345,000 dialysis patients around the world. Their well-being always comes first. Since Fresenius Medical Care was founded in 1996, our aim has been to improve our patients’ quality of life by offering them high-quality products as well as innovative technologies and therapies. 

With around 123,000 employees today, we intend to grow further and continue to use our experience, innovative research and value-based care approach to provide the best possible care for our patients. 2021 and the COVID-19 pandemic reminded us once again of the vulnerable patient population we serve and also showed the commitment of our employees to our patients.

Revenue

Revenue growth at constant currency achieved

NORTH AMERICA

EUROPE, MIDDLE EAST AND AFRICA

ASIA-PACIFIC

LATIN AMERICA

HEALTH CARE SERVICES

HEALTH CARE PRODUCTS

2020 €17.86 BN
2021 €17.62 BN

Operating
Income

Earnings development affected by COVID-19

1At constant currency

22021: costs related to the FME25 program; 2020: impairment of goodwill and trade names in the Latin America segment

Net
Income

Results in line with guidance despite stronger-than-anticipated headwinds

1At constant currency

2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

32021: costs related to the FME25 program; 2020: impairment of goodwill and trade names in the Latin America segment

Dividend

25th consecutive dividend increase to be proposed

1Proposal to be approved by the Annual General Meeting on May 12, 2022

2017 €1.06
2018 €1.17
2019 €1.20

EMPLOYEES

Our employees showed their unwavering commitment to our patients

1Full-time equivalents

2019 120,6591 employees
2020 125,3641 employees